Literature DB >> 10701150

How to do without steroids in inflammatory bowel disease.

D H Present1.   

Abstract

This review covers the use of steroids in the treatment of both ulcerative colitis and Crohn's disease. It looks at controlled trials and uncontrolled trials as to the benefits of this agent in both inducing and maintaining remission. The review also stresses the high incidence of toxicity with prolonged use of steroids and the fact that controlled trials have clearly shown that steroids do not maintain remission in either disorder. Alternatives to initiating steroids in mild to moderately active ulcerative colitis and Crohn's disease are presented. The use of steroids in fistulizing versus nonfistulizing Crohn's is also covered. Finally, there is a review of data and discussion of the role of antibiotics, immunosuppressives, and combination therapy for both ulcerative colitis and Crohn's disease. The expectation is that the reader will consider alternatives to initiating and maintaining steroids for prolonged periods of time in the treatment of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10701150     DOI: 10.1097/00054725-200002000-00009

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  21 in total

Review 1.  A perspective on inflammatory bowel disease in the child and adolescent at the turn of the millennium.

Authors:  C Haller; J Markowitz
Journal:  Curr Gastroenterol Rep       Date:  2001-06

2.  Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study.

Authors:  Ken Fukunaga; Kazuko Nagase; Takeshi Kusaka; Nobuyuki Hida; Yoshio Ohda; Koji Yoshida; Katsuyuki Tozawa; Koji Kamikozuru; M Iimuro; Shiro Nakamura; Hiroto Miwa; Takayuki Matsumoto
Journal:  Gut Liver       Date:  2009-03-31       Impact factor: 4.519

Review 3.  Antibiotics and probiotics in treatment of inflammatory bowel disease.

Authors:  Paolo Gionchetti; Fernando Rizzello; Karen-M Lammers; Claudia Morselli; Lucia Sollazzi; Samuel Davies; Rosy Tambasco; Carlo Calabrese; Massimo Campieri
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

4.  European evidence based consensus on the diagnosis and management of Crohn's disease: special situations.

Authors:  R Caprilli; M A Gassull; J C Escher; G Moser; P Munkholm; A Forbes; D W Hommes; H Lochs; E Angelucci; A Cocco; B Vucelic; H Hildebrand; S Kolacek; L Riis; M Lukas; R de Franchis; M Hamilton; G Jantschek; P Michetti; C O'Morain; M M Anwar; J L Freitas; I A Mouzas; F Baert; R Mitchell; C J Hawkey
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

5.  Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report.

Authors:  K Makiyama; F Takeshima; T Hamamoto
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

Review 6.  Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.

Authors:  Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

7.  Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes.

Authors:  Naoki Yoshimura; Tokuma Tadami; Takaaki Kawaguchi; Minako Sako; Hiroshi Yoshimoto; Toshihiko Yamaka; Masakazu Takazoe
Journal:  J Gastroenterol       Date:  2011-09-14       Impact factor: 7.527

Review 8.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

9.  Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease.

Authors:  Annelie Lindberg; Michael Eberhardson; Mats Karlsson; Per Karlén
Journal:  BMC Gastroenterol       Date:  2010-07-06       Impact factor: 3.067

10.  Leukocyte apheresis in the management of ulcerative colitis.

Authors:  Ahmed Helmy; Maheeba Abdulla; Ingvar Kagevi; Khalid Al Kahtani
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.